STAT3 Gene - Signal Transducer and Activator of Transcription 3

A critical transcription factor in cytokine signaling, immunity, and cancer

Gene Information Card

Symbol STAT3
Full Name Signal transducer and activator of transcription 3
Gene Type Protein coding
Chromosomal Location 17q21.2
NCBI Gene ID 6774 ncbi.nlm.nih.gov/gene/6774
Ensembl ID ENSG00000168610
UniProt ID P40763
OMIM ID 102582
HGNC ID 11364
Aliases APRF, HIES, ADMIO, MGC17067

Description

The STAT3 gene encodes a transcription factor that mediates cellular responses to various cytokines and growth factors. It plays a central role in immune regulation, cell proliferation, differentiation, and survival. STAT3 is activated by phosphorylation via JAK kinases in response to interleukins (e.g., IL-6, IL-10) and growth factors, leading to dimerization, nuclear translocation, and target gene transcription. Dysregulation of STAT3 signaling is implicated in numerous diseases, including immunodeficiencies, autoimmune disorders, and cancers.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Autosomal dominant hyper-IgE syndrome (Job syndrome) Loss-of-function mutations in STAT3 impair Th17 cell differentiation and IL-6/IL-10 signaling, leading to recurrent infections, eczema, and skeletal abnormalities. OMIM #147060; ClinVar
Autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) Gain-of-function mutations or overactivation of STAT3 promote pro-inflammatory cytokine production and T-cell dysregulation. OMIM #102582; PubMed
Various cancers (e.g., breast, lung, colorectal, lymphoma) Constitutive activation of STAT3 (via phosphorylation) drives oncogenic gene expression, promoting proliferation, survival, angiogenesis, and immune evasion. COSMIC; PubMed
STAT3-related early-onset multisystem autoimmune disease Gain-of-function mutations in STAT3 cause lymphoproliferation, autoimmune cytopenias, and interstitial lung disease. OMIM #615952; ClinVar
Hepatocellular carcinoma STAT3 activation in liver cells promotes tumor growth and metastasis through upregulation of anti-apoptotic and proliferative genes. COSMIC; PubMed

Expression Profile

Tissue Expression
Tissue nTPM level
Liver 20.1 High
Bone marrow 15.3 Medium
Lung 12.8 Medium
Spleen 11.5 Medium
Kidney 9.2 Low
Brain 6.4 Low
Cell Line Expression
Cell Line nTPM Notes
K-562 (leukemia) 25.3 High expression; constitutive activation in CML
HeLa (cervical cancer) 18.7 Moderate; responsive to IL-6
A549 (lung cancer) 22.1 High; associated with oncogenic signaling
MCF7 (breast cancer) 14.5 Moderate; estrogen receptor positive
HepG2 (liver cancer) 19.8 High; involved in acute phase response
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
R382W Missense Rare (germline) Loss-of-function; associated with hyper-IgE syndrome
V637M Missense Rare (germline) Gain-of-function; causes autoimmune disease
D661Y Missense Somatic (cancer) Gain-of-function; constitutive activation in various tumors
K658N Missense Somatic (cancer) Gain-of-function; promotes oncogenic transcription
Y705F Missense Somatic (cancer) Loss of phosphorylation site; dominant-negative effect
Mutation functional classification

Loss of Function (LOF)

Loss-of-function mutations in STAT3, typically in the DNA-binding or SH2 domains, impair its transcriptional activity, leading to immunodeficiency (e.g., hyper-IgE syndrome) and defective Th17 cell differentiation.

Gain of Function (GOF)

Gain-of-function mutations, often in the SH2 domain or C-terminal region, enhance STAT3 activation and nuclear signaling, resulting in autoimmune disorders and oncogenic transformation.

Dominant Negative (DN)

Dominant-negative mutations produce a STAT3 protein that can dimerize with wild-type STAT3 but lacks transcriptional activity, thereby suppressing normal signaling. These are commonly seen in hyper-IgE syndrome.

Gene Ontology (GO)

• DNA-binding transcription factor activity • RNA polymerase II cis-regulatory region sequence-specific DNA binding
• Signal transducer activity • Protein homodimerization activity
• Cytokine receptor binding • Kinase binding
• Transcription coregulator binding • Nucleus
• Cytoplasm • Cellular response to cytokine stimulus
• Regulation of cell population proliferation • Inflammatory response
• Immune response

Pathways

• JAK-STAT signaling pathway
• IL-6 signaling pathway
• IL-10 signaling pathway
• IL-23 signaling pathway
• PD-L1 expression and PD-1 checkpoint pathway in cancer
• Th17 cell differentiation
• Acute phase response
• EGFR tyrosine kinase inhibitor resistance

Protein Summary

STAT3 is a 770-amino acid protein with a molecular weight of ~88 kDa. It contains conserved domains: an N-terminal domain, a coiled-coil domain, a DNA-binding domain, a SH2 domain, and a C-terminal transactivation domain. Upon cytokine stimulation, JAK kinases phosphorylate STAT3 at tyrosine 705, inducing dimerization and nuclear translocation. In the nucleus, STAT3 binds to specific DNA response elements to regulate gene expression. STAT3 also undergoes acetylation and phosphorylation at serine 727, modulating its activity. It interacts with various coactivators and corepressors, influencing a wide range of biological processes.

Related Products

Product name Cat.No. Species Gene ID
Stat3 Knockout CT26.WT Cell Line EDJ-KZ496 Mouse 20848 Details Get a Quote
STAT3 Knockout HCT 116 Cell Line EDJ-KQ21089 Human 6774 Details Get a Quote
STAT3 Knockout A-549 Cell Line EDJ-KQ21087 Human 6774 Details Get a Quote
STAT3 Knockout HeLa Cell Line EDJ-KQ18072 Human 6774 Details Get a Quote
STAT3 Knockout HEK293 Cell Line EDJ-KQ903 Human 6774 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: